Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey R Zeiser, A Burchert, C Lengerke, M Verbeek, K Maas-Bauer, ... Leukemia 29 (10), 2062-2068, 2015 | 589 | 2015 |
New drugs, new toxicities: severe side effects of modern targeted and immunotherapy of cancer and their management F Kroschinsky, F Stölzel, S von Bonin, G Beutel, M Kochanek, M Kiehl, ... Critical Care 21, 1-11, 2017 | 428 | 2017 |
Treatment of refractory acute GVHD with third-party MSC expanded in platelet lysate-containing medium M Von Bonin, F Stölzel, A Goedecke, K Richter, N Wuschek, K Hölig, ... Bone marrow transplantation 43 (3), 245-251, 2009 | 386 | 2009 |
Long-term prognosis of acute myeloid leukemia according to the new genetic risk classification of the European LeukemiaNet recommendations: evaluation of the proposed reporting … C Röllig, M Bornhäuser, C Thiede, F Taube, M Kramer, B Mohr, W Aulitzky, ... Journal of clinical oncology 29 (20), 2758-2765, 2011 | 316 | 2011 |
Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2 … U Platzbecker, JM Middeke, K Sockel, R Herbst, D Wolf, CD Baldus, ... The Lancet Oncology 19 (12), 1668-1679, 2018 | 287 | 2018 |
Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells NR Mathew, F Baumgartner, L Braun, D O'Sullivan, S Thomas, ... Nature medicine 24 (3), 282-291, 2018 | 261 | 2018 |
A novel prognostic model in elderly patients with acute myeloid leukemia: results of 909 patients entered into the prospective AML96 trial C Röllig, C Thiede, M Gramatzki, W Aulitzky, H Bodenstein, M Bornhäuser, ... Blood, The Journal of the American Society of Hematology 116 (6), 971-978, 2010 | 229 | 2010 |
Loss of the histone methyltransferase EZH2 induces resistance to multiple drugs in acute myeloid leukemia S Göllner, T Oellerich, S Agrawal-Singh, T Schenk, HU Klein, C Rohde, ... Nature medicine 23 (1), 69-78, 2017 | 226 | 2017 |
Bone marrow central memory and memory stem T-cell exhaustion in AML patients relapsing after HSCT M Noviello, F Manfredi, E Ruggiero, T Perini, G Oliveira, F Cortesi, ... Nature communications 10 (1), 1065, 2019 | 139 | 2019 |
18F-FDG-PET/CT for detection of extramedullary acute myeloid leukemia F Stölzel, C Röllig, J Radke, B Mohr, U Platzbecker, M Bornhäuser, ... Haematologica 96 (10), 1552, 2011 | 127 | 2011 |
Mesenchymal stromal cells for treatment of acute steroid-refractory graft versus host disease: clinical responses and long-term outcome F von Dalowski, M Kramer, M Wermke, R Wehner, C Röllig, N Alakel, ... Stem Cells 34 (2), 357-366, 2016 | 118 | 2016 |
Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or … DW Beelen, R Trenschel, M Stelljes, C Groth, T Masszi, P Reményi, ... The Lancet Haematology 7 (1), e28-e39, 2020 | 116 | 2020 |
Isolated trisomy 13 defines a homogeneous AML subgroup with high frequency of mutations in spliceosome genes and poor prognosis T Herold, KH Metzeler, S Vosberg, L Hartmann, C Röllig, F Stölzel, ... Blood, The Journal of the American Society of Hematology 124 (8), 1304-1311, 2014 | 111 | 2014 |
TP53 abnormalities correlate with immune infiltration and associate with response to flotetuzumab immunotherapy in AML J Vadakekolathu, C Lai, S Reeder, SE Church, T Hood, A Lourdusamy, ... Blood advances 4 (20), 5011-5024, 2020 | 108 | 2020 |
Does time from diagnosis to treatment affect the prognosis of patients with newly diagnosed acute myeloid leukemia? C Röllig, M Kramer, C Schliemann, JH Mikesch, B Steffen, A Krämer, ... Blood, The Journal of the American Society of Hematology 136 (7), 823-830, 2020 | 102 | 2020 |
Karyotype complexity and prognosis in acute myeloid leukemia F Stölzel, B Mohr, M Kramer, U Oelschlägel, T Bochtler, WE Berdel, ... Blood cancer journal 6 (1), e386-e386, 2016 | 100 | 2016 |
CEBPA mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome F Taube, JA Georgi, M Kramer, S Stasik, JM Middeke, C Röllig, U Krug, ... Blood, The Journal of the American Society of Hematology 139 (1), 87-103, 2022 | 99 | 2022 |
TP53 mutation in patients with high‐risk acute myeloid leukaemia treated with allogeneic haematopoietic stem cell transplantation JM Middeke, S Herold, E Rücker‐Braun, WE Berdel, M Stelljes, ... British journal of haematology 172 (6), 914-922, 2016 | 95 | 2016 |
Chromosomal Abnormalities and Prognosis in NPM1-Mutated Acute Myeloid Leukemia: A Pooled Analysis of Individual Patient Data From Nine International Cohorts L Angenendt, C Röllig, P Montesinos, D Martinez-Cuadron, E Barragan, ... Journal of Clinical Oncology 37 (29), 2632-2642, 2019 | 93 | 2019 |
Clonal heterogeneity as detected by metaphase karyotyping is an indicator of poor prognosis in acute myeloid leukemia T Bochtler, F Stölzel, CE Heilig, C Kunz, B Mohr, A Jauch, JWG Janssen, ... Journal of clinical oncology 31 (31), 3898-3905, 2013 | 82 | 2013 |